Ron Bentsur Acquires 12,500 Shares of Nuvectis Pharma (NASDAQ:NVCT) Stock

Nuvectis Pharma, Inc. (NASDAQ:NVCT) CEO Ron Bentsur acquired 12,500 shares of the firm’s stock in a transaction on Tuesday, June 30th. The shares were bought at an average cost of $20.00 per share, with a total value of $250,000.00. Following the completion of the acquisition, the chief executive officer directly owned 3,688,424 shares in the company, valued at approximately $73,768,480. This represents a 0.34% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Nuvectis Pharma Stock Up 0.3%

NVCT stock opened at $19.57 on Friday. Nuvectis Pharma, Inc. has a twelve month low of $5.55 and a twelve month high of $29.27. The stock’s 50 day moving average is $12.50 and its 200-day moving average is $9.83. The firm has a market capitalization of $519.19 million, a PE ratio of -14.94 and a beta of -0.24.

Nuvectis Pharma (NASDAQ:NVCT) last announced its earnings results on Tuesday, May 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.04. On average, equities research analysts anticipate that Nuvectis Pharma, Inc. will post -1.01 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

NVCT has been the subject of several recent analyst reports. Wall Street Zen upgraded shares of Nuvectis Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Nuvectis Pharma in a research report on Friday, June 5th. Finally, HC Wainwright boosted their price target on shares of Nuvectis Pharma from $13.00 to $39.00 and gave the stock a “buy” rating in a report on Monday, June 22nd. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $39.00.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Goldman Sachs Group Inc. bought a new position in Nuvectis Pharma in the 1st quarter valued at $446,000. Jane Street Group LLC bought a new stake in shares of Nuvectis Pharma during the 1st quarter worth $413,000. Geode Capital Management LLC boosted its holdings in shares of Nuvectis Pharma by 110.8% in the 2nd quarter. Geode Capital Management LLC now owns 285,332 shares of the company’s stock worth $2,132,000 after buying an additional 149,999 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Nuvectis Pharma by 3,398.9% in the 2nd quarter. JPMorgan Chase & Co. now owns 6,263 shares of the company’s stock worth $47,000 after buying an additional 6,084 shares during the last quarter. Finally, New York State Common Retirement Fund bought a new position in Nuvectis Pharma during the second quarter valued at about $97,000. Hedge funds and other institutional investors own 96.77% of the company’s stock.

Nuvectis Pharma Company Profile

Nuvectis Pharma is a clinical-stage biotechnology company focused on the development of novel peptide-based therapeutics using its proprietary Cellporting delivery platform. The company’s core technology is designed to facilitate the transport of therapeutic proteins and peptides across cellular membranes and into target intracellular compartments, including the nucleus. By overcoming a key barrier in biologics delivery, Nuvectis aims to expand the range of treatable diseases with macromolecular drugs that have traditionally been limited by poor cellular uptake.

The Nuvectis pipeline encompasses multiple preclinical and early-stage clinical programs targeting rare genetic and metabolic disorders.